Comparative Pharmacology
Head-to-head clinical analysis: CORTENEMA versus KENACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTENEMA versus KENACORT.
CORTENEMA vs KENACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, decrease cytokine production, and suppress inflammatory cell migration and activation in the colonic mucosa.
Glucocorticoid receptor agonist; inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis; suppresses cytokine production and immune cell migration.
One enema (100 mg hydrocortisone in 60 mL) administered rectally once daily, preferably at bedtime, for 21 days or until clinical response.
Kenacort (triamcinolone acetonide) is a corticosteroid. For adults, typical dosing is 40-80 mg intramuscularly (deep intragluteal) as a single injection; oral tablets: 4-48 mg/day divided every 6-12 hours; intra-articular: 5-40 mg depending on joint size.
None Documented
None Documented
1.8-3.5 hours (plasma); due to rectal administration and low systemic absorption, clinical effects persist longer than plasma levels suggest
Terminal elimination half-life: 2-5 hours (triamcinolone acetonide). Clinical context: Short half-life supports alternate-day dosing for chronic conditions; however, adrenal suppression may persist longer.
Primarily hepatic metabolism with renal excretion of inactive metabolites; <5% unchanged in urine; biliary/fecal elimination of metabolites accounts for ~80%
Renal: 25-30% as unchanged drug and metabolites. Biliary/fecal: 50-70% as metabolites, with enterohepatic circulation.
Category C
Category C
Corticosteroid
Corticosteroid